B. Other related parties with whom transactions have taken place during the year:

I) Fellow subsidiaries :

British Colloids Ltd., U.K.
Abbott Healthcare Products Ltd., U.K
Abbott Healthcare Private Ltd, India
Abbott International LLC, USA
Abbott Products Operations AG. Switzerland
Abbott Laboratories (Singapore) Pte Ltd., Singapore
Abbott GmbH & Co. K.G., Germany
Alere Medical Private Limited, India
Abbott Laboratories S.A., Dubai
Abbott Laboratories S.C., Srilanka
St Jude Medical India Private Limited, India

II) Key Management Personnel (including Independent Directors):

Mr. Anil Joseph, Managing Director (w.e.f. July 1, 2020)	
Mr. Rajiv Sonalker, Whole-Time Director	
Mr. Munir Shaikh, Chairman, Non-Executive Director	
Ms. Anisha Motwani, Independent Director	
Mr. Sudarshan Jain, Independent Director	
Ms. Shalini Kamath, Independent Director	

C. Transactions during the year :

(I) Transactions with the Holding Company during the year	(Rupees in Lakhs)
	Period from April 1, 2020 to
	September 30, 2020
Abbott Capital India Ltd., UK	
Remittance of Dividend	26,797.74

(II) Transactions with Fellow Subsidiaries during the year

(i) Remittance of dividend :

	Period from April 1, 2020 to September 30, 2020
British Colloids Ltd., U.K.	
Remittance of Dividend	3,675.00
Abbott Healthcare Products Ltd., U.K	
Remittance of Dividend	9,362.38

(ii) Sales to fellow subsidiaries :

	Period from April 1, 2020 to
	September 30, 2020
Abbott Healthcare Private Ltd, India	
Sales of Stock-in-trade	2,594.33
Sales of Raw Materials	48.40

(iii) Purchases from fellow subsidiaries:

	Period from April 1, 2020 to
	September 30, 2020
Abbott Healthcare Private Ltd, India	
Purchase of Raw Materials	2.86
Purchase of Stock-in-trade	4,070.98
Abbott Products Operations AG. Switzerland	
Purchase of Raw Materials	16,831.97
Purchase of Stock-in-trade	4,298.87

	Period from April 1, 2020 to
	September 30, 2020
Abbott Healthcare Private Ltd, India	
Promotional Expenses	31.38
Conversion charges	836.35
Alere Medical Pvt. Ltd., India	
Promotional Expenses	6.03

(v) Loan /deposit and Interest to/from fellow subsidiaries :

	Period from April 1, 2020 to
	September 30, 2020
Abbott Healthcare Private Ltd, India	
Interest free additional security deposit paid	16.44

(vi) Reimbursements to and from fellow subsidiaries:

	Reimbursement to	Reimbursement from
	Period from April 1, 2020 to	Period from April 1, 2020 to
	September 30, 2020	September 30, 2020
Abbott Healthcare Private Ltd, India		
Shared and support Services	2,589.84	-
Rent Expenses	1,697.10	-
Market Research and other Expenses	-	26.48
Abbott International LLC, USA		
Employee Benefit Expenses, Travel and other Expenses	2.55	-
Abbott Laboratories (Singapore) Pte Ltd., Singapore		
Employee Benefit Expenses, Travel and other Expenses	0.40	14.10
Abbott GmbH, Germany		
Employee Benefit Expenses, Travel and other Expenses	-	3.88
Abbott Laboratories S.C., Srilanka		
Employee Benefit Expenses, Travel and other Expenses	-	24.03

(vii) Income from fellow subsidiaries:

	Period from April 1, 2020 to
	September 30, 2020
Abbott Healthcare Private Ltd, India	
Shared and support services	2,495.78
Rent Income	57.26
Abbott Products Operations AG., Switzerland	
Shared and support services	114.23
Abbott Laboratories (Singapore) Pte, Singapore	
Shared and support services	47.35
Abbott Laboratories S.A., Dubai	
Shared and support services	47.35
St Jude Medical India Private Limited, India	
Shared and support services	61.56
Alere Medical Pvt. Ltd., India	
Shared and support services	2.09

(viii) Key Management Personnel Remuneration :

	Period from April 1, 2020 to
	September 30, 2020
Remuneration to Key Management Personnel *	170.25

*(Provision for post employment benefits as contribution to gratuity fund, leave encashment on retirement and other defined benefits which are made based on actuarial valuation on an overall Company basis are not included here)

	Period from April 1, 2020 to September 30, 2020
Sitting Fees to Independent and Non-Executive Directors	32.00

As at
September 30, 2020
10,341.06
1,885.56
12,226.61
2.49
0.39
2.89
1,070.49
1,070.49
317.70
23.76
2.60
0.98
8.98
8.98
11.34
2.80
2.09
379.22
1,484.12

All transactions with related parties are made in the ordinary course of business and the same is at arm's length. Outstanding balances at the year-end are unsecured and settlement occurs in cash. The Company has not recorded any impairment of receivables. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which related party

operates.